logo
Share SHARE
FONT-SIZE Plus   Neg

Ultragenyx Pharma Posts Wider Loss In Q3 - Quick Facts

Ultragenyx Pharmaceutical Inc. (RARE) reported a third-quarter net loss of $79.2 million, or $1.87 per share, compared to a net loss of $64.9 million, or $1.64 per share, prior year. On average, 16 analysts polled by Thomson Reuters expected the company to report a loss per share of $1.86 for the quarter. Analysts' estimates typically exclude special items.

"Burosumab and vestronidase alfa regulatory submissions have been accepted and regulatory review is progressing well in both the US and European Union. We are preparing for a near-term potential launch of vestronidase alfa with a PDUFA date of November 16," said Emil Kakkis, CEO of Ultragenyx.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Uber has mistakenly charged a customer in Toronto an astounding C$18,518.50 for a five-mile, 21-minute ride. In U.S. dollar terms, the amount would be more than $14,400. The five-mile ride should have only cost between C$12 and C$16. French baby formula maker Lactalis has issued a major international product recall over fears of salmonella contamination. French health authorities have ordered the dairy company to stop selling hundreds of products worldwide, after 26 infants fell ill with salmonella poisoning in France. Salmonella infections can be life-threatening mainly for young children. What's in store for Casey's General Stores Inc. (CASY), KMG Chemicals Inc. (KMG), and Yingli Green Energy Holding Co. Ltd. (YGE) in today's earnings announcement?
comments powered by Disqus
Follow RTT